/ /

  • linkedin
  • Increase Font
  • Sharebar

    B + L dedicated to eye care with strong portfolio, new programs

    Bausch + Lomb (B + L) is one of the oldest commercial names in eye care with one of broadest product portfolios in the ophthalmic industry. Valeant Pharmaceuticals’ acquisition of the company has not changed B + L’s dedication to eye care or its continuing investment in glaucoma and other eye care categories.

    More: Evidence-based answers to lifestyle questions on glaucoma

    “We, Valeant, are a collection of great healthcare franchises and brands that exist globally,” said Tracy M. Valorie, senior vice president and general manager of ophthalmology Rx at B + L. “We have a lot of talented people who continue to evolve our portfolio and continue to deliver products and services in a vast array of areas, ophthalmology being one of them. One of the greatest challenges in health care is ensuring that patients can actually receive products once they are approved. At Valeant, we have a relentless focus on creative ways to help patients to gain access to products at reasonable prices.”

    Valorie discussed the role of B + L in the larger Valeant organization during an Industry Spotlight presentation at the 2016 Glaucoma 360 meeting. B + L accounts for 10% of Valeant’s total portfolio in the United States. B+L’s ophthalmic lines account for even larger proportions of Valeant’s revenues in Asia, Europe, Latin America, and other regions. She said Valeant is leveraging its broad portfolio reach to bolster sales by focusing on patient access and pricing issues.

    Walgreens partnership

    Valeant recently announced a 20-year partnership with Walgreens to improve patient access to health care at affordable pricing. The initial access program is focusing on three patient care areas: women’s health, dermatology, and ophthalmology.

    “This program is a real opportunity for patients you treat with B + L products,” Valorie said. “You now know that they will get precisely the product you wrote for at an affordable price.”

    More G360: Numerous issues underlie unexplainable glaucoma progression

    Acquisition also has helped B + L focus on new products and programs that lead to expanded growth opportunities, she continued. While all Valeant units are focused on growth, B + L brings a deep research-and-development bench in eye care. In addition to traditional strengths in consumer, contact lenses, vision care, and surgical, B + L is also focusing on pharmaceuticals.

    “Eye care is all we do at B + L,” Valorie said. “When you look across the breadth and depth of our portfolio, we can treat pretty much anything you see across the slit lamp. Not all of our brands are the biggest in the market, but we have the opportunity to work with each of the areas you focus on.”

    Strong portfolio

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results